BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® Program
February 08 2023 - 9:00AM
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the
“Company”) (NASDAQ:BRTX
), a clinical stage company
focused on stem cell-based therapies, today announced that the
European Patent Office has issued a notice of allowance for a
patent application related to the Company’s metabolic ThermoStem®
program. The notice of allowance was issued on February 6, 2023.
Claims granted under the new patent cover
implantable three-dimensional scaffolds and brown adipocytes that
have been derived from human brown adipose-derived stem cells. The
therapeutic combination of scaffolds as a delivery system and brown
adipose-derived stem cells provides the ability to deliver
metabolically active cells. Therapeutic benefits of using brown
adipose have been demonstrated in various models and may provide a
valuable therapeutic tool for treating a range of metabolic
disorders in multi-billion dollar markets. Certain companies that
use encapsulation technology coupled with cells have shown
promising clinical results treating type 1 diabetes in their Phase
1/2 clinical trials.
“Our patent family for our ThermoStem® program
continues to grow as we receive additional patent grants in key
markets,” said Lance Alstodt, the Company’s CEO. “We are committed
to the development of ThermoStem® as a potential treatment for
obesity and metabolic disorders, such as type 2 diabetes. This
patent, which covers a manufacturing process for ThermoStem®
developed by BioRestorative’s scientists, enhances our ability to
do so in European jurisdictions.”
About BioRestorative
Therapies, Inc.
BioRestorative Therapies, Inc.
(www.biorestorative.com) develops therapeutic products using cell
and tissue protocols, primarily involving adult stem cells. Our two
core programs, as described below, relate to the treatment of
disc/spine disease and metabolic disorders:
• Disc/Spine Program (brtxDISC™): Our lead cell
therapy candidate, BRTX-100, is a product formulated from
autologous (or a person’s own) cultured mesenchymal stem cells
collected from the patient’s bone marrow. We intend that the
product will be used for the non-surgical treatment of painful
lumbosacral disc disorders or as a complementary therapeutic to a
surgical procedure. The BRTX-100 production process
utilizes proprietary technology and involves collecting a patient’s
bone marrow, isolating and culturing stem cells from the bone
marrow and cryopreserving the cells. In an outpatient
procedure, BRTX-100 is to be injected by a physician into
the patient’s damaged disc. The treatment is intended for patients
whose pain has not been alleviated by non-invasive procedures and
who potentially face the prospect of surgery. We have commenced a
Phase 2 clinical trial using BRTX-100 to treat chronic
lower back pain arising from degenerative disc disease.
• Metabolic Program (ThermoStem®): We are
developing a cell-based therapy candidate to target obesity and
metabolic disorders using brown adipose (fat) derived stem cells to
generate brown adipose tissue (“BAT”). BAT is intended to mimic
naturally occurring brown adipose depots that regulate metabolic
homeostasis in humans. Initial preclinical research indicates that
increased amounts of brown fat in animals may be responsible for
additional caloric burning as well as reduced glucose and lipid
levels. Researchers have found that people with higher levels of
brown fat may have a reduced risk for obesity and
diabetes.
Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. You are cautioned that such
statements are subject to a multitude of risks and uncertainties
that could cause future circumstances, events or results to differ
materially from those projected in the forward-looking statements
as a result of various factors and other risks, including, without
limitation, those set forth in the Company's latest Form 10-K filed
with the Securities and Exchange Commission. You should consider
these factors in evaluating the forward-looking statements included
herein, and not place undue reliance on such statements. The
forward-looking statements in this release are made as of the date
hereof and the Company undertakes no obligation to update such
statements.
CONTACT:Email: ir@biorestorative.com
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Sep 2023 to Sep 2024